Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Target Oncol. 2010 Mar;5(1):59-63. doi: 10.1007/s11523-010-0133-x. Epub 2010 Mar 23.
Hepatocellular carcinoma (HCC) is a highly aggressive cancer. For patients who are diagnosed with advanced stage disease that are not surgical candidates, the disease is universally lethal. Advance has been made to extend survival with molecular target therapy, but durable complete responses are extremely rare. We report an unusual case where a 74-year-old patient with unresectable HCC received eight months of reduced-dose of sorafenib, a tyrosine kinase inhibitor, and achieved a durable complete remission. At the most recent follow up, he remains in remission 16 months after cessation of treatment, without clinical or imaging evidence of disease recurrence.
肝细胞癌（HCC）是一种侵袭性很强的癌症。对于那些被诊断为晚期且不适合手术的患者，这种疾病是普遍致命的。随着分子靶向治疗的进步，已经可以延长生存时间，但完全持久缓解的情况极为罕见。我们报告了一个不常见的病例，一名 74 岁的不可切除 HCC 患者接受了 8 个月的索拉非尼（一种酪氨酸激酶抑制剂）低剂量治疗，并实现了持久的完全缓解。在最近的随访中，他在停止治疗 16 个月后仍处于缓解状态，没有疾病复发的临床或影像学证据。
